Phase
Condition
Heart Failure
Myasthenia Gravis (Chronic Weakness)
Chest Pain
Treatment
Ensure Original
Ensure Max Protein
Clinical Study ID
Ages 18-100 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Left ventricular ejection fraction (LVEF) ≤40%, New York Heart Association (NHYA)class II to IV symptoms or N-terminal pro B-natriuretic peptide (NT-proBNP) >300pg/mL
Age 18 years to 100 years, inclusive
Receiving guideline-directed medical therapy (GDMT), unless contraindicated or nottolerated
Any of the following markers of severe HF within prior 12 months: i) Inotropictherapy; ii) 1 or more HF hospitalizations; iii) LVEF ≤25%; iv) Peak oxygenconsumption (VO2) <50% predicted or ≤16 mL/kg/min; v) 6-minute walk distance <300meters; vi) Unintentional weight loss >5% of bodyweight over the past year; vii)Moderate or severe muscle wasting on physical examination; viii) NT-proBNP ≥900pg/mL
Exclusion
Exclusion Criteria:
Pregnancy, planning to become pregnant, or women of reproductive potential unwillingto complete pre-DXA urine pregnancy test before first DXA or randomization
History of left ventricular assist device (LVAD), heart transplantation, orestimated glomerular filtration rate (eGFR) <20 mL/min/1.73 m2
An identified clinical disorder associated with skeletal muscle weakness/wasting (e.g., muscular dystrophy, mitochondrial disorder, active cancer, modified Rankinscore greater or equal to 4 post-stroke)
Milk allergy, protein allergy, lactose intolerance, and galactosemia
Weight ≥350 pounds and/or BMI ≥40 kg/m2
Study Design
Connect with a study center
Tufts Medical Center
Boston, Massachusetts 02111
United StatesActive - Recruiting
Cleveland Clinic
Cleveland, Ohio 44195
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.